Table of Contents Table of Contents
Previous Page  338 / 812 Next Page
Information
Show Menu
Previous Page 338 / 812 Next Page
Page Background

S334

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

EW623

Antipsychotic monotherapy versus

combination in schizophrenia: Are

there differences in cognition?

A. Ruiz

1

, A. Bra˜nas

1

, M. Vicens

1

, A. Orozco

1

, G. Lahera

2 ,

1

Príncipe de Asturias University Hospital, Psychiatry, Alcalá- Madrid,

Spain

2

University of Alcalá- IRyCIS- CIBERSAM, Medicine and Medical

Specialties, Madrid, Spain

Corresponding author.

Introduction

Influential protocols in the treatment of schizophre-

nia recommend the use of antipsychotics inmonotherapy, although

combination is common in clinical practice.

Objectives/aims

To compare cognitive performance of patients

with schizophrenia treated by antipsychotic monotherapy or

polytherapy; secondly, to analyze clinical and sociodemographic

differences.

Methods

Ninety-eight outpatients between 18 and 65 years,

diagnosedwith schizophrenia, based on the DSM-Vwere recruited.

Seventywere inmonotherapy and 28 in antipsychotic combination.

Patients with comorbidity, moderate to severe motor impregna-

tion, abuse-substance dependence or serious somatic illness were

excluded. Both groups were compared in sociodemographic, clin-

ical and cognitive measures: PANSS scale, short Akathisia Scale

Simpson-Angus Scale, State-Trait Anxiety Inventory (STAI), face

emotion recognition (FEIT) and global Functioning (GAF), speed

processing - through the Trail Making Test, parte A, subtest of

symbol coding of the Brief Assessment of Cognition in Schizophre-

nia (BACS) and Verbal fluency (animals)- and sustained attention

(SA)–through the Continuous Performance Test (CPT).

Results

Both groups showed similar age, gender, number of hos-

pitalizations, score in STAI-Trait, STAI-State, ANGUS, GAF, TMT-A,

verbal fluency and face emotion recognition. Patients in polither-

apy had more years of evolution (

P

0.047), higher score in positive

PANSS (

P

0.007), negative PANSS (

P

0.008), general PANSS (

P

0.001);

they showed more detection errors in the CPT (

P

0008), and a trend

towards less processing speed through the symbol coding (

P

0.063),

compared to patients in monotherapy.

Conclusions

Antipsychotic polipharmacy is associated with an

impairment in sustained attention in patients with schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.741

EW624

DECIDE study: Effectiveness of shared

decision making in treatment

planning at discharge of inpatient

with schizophrenia: Half sample

interim analysis, preliminary

conclusions

J. Pérez Revuelta

1 ,

, I. Lara Ruiz-Granados

2

, F. Gonzalez Saiz

3

,

J.M. Pascual Pa˜no

3

, J.M. VIllagran Moreno

3

1

Servicio Andaluz Salud, Fundacion Biomedica Cadiz - Clinical

Management Unit of Mental Health, Jerez de la Frontera, Spain

2

Servicio Andaluz Salud, Macarena Clinical Management Unit of

Mental Health, Sevilla, Spain

3

Servicio Andaluz Salud, Clinical Management Unit of Mental Health,

Jerez de la Frontera, Spain

Corresponding author.

DECIDE Study

Effectiveness of shared decision making in treat-

ment planning at discharge of inpatient with schizophrenia:

interim analysis.

Introduction

Shared decision-making denotes a structured pro-

cess that encourages full participation by patient and provider in

making complex medical decisions. Hamann et al. conducted a

few years ago a randomized controlled trial with schizophrenic

inpatients and found increased knowledge and perceived involve-

ment in decisions about antipsychotic treatment at discharge by

the experimental group, but not clear beneficial effects on long

termoutcomes. The present communication introduces theDECIDE

study.

Aims and objectives

Of the study: to demonstrate the effective-

ness, measured as treatment adherence and readmissions at 3,

6 and 12 months, of shared decision making in the choice of

antipsychotic treatment at discharge in a simple of schizophren-

ics hospitalized after an acute episode of their disorder. Of the oral

presentation: to present preliminary conclusions with more of the

half of the sample.

Methods

Randomized controlled trial, prospective, two parallel

groups, not masked, comparing two interventions (shared deci-

sion making and treatment as usual). Study population: inpatients

diagnosed of schizophrenia and schizoaffective disorders (ICD-

10/DSM-IV-R: F20 y F25) at Adult Acute Hospitalization Unit at

Jerez General Hospital.

Results

At discharge, increased scale score COMRADE, both sub-

scales (Satisfacción in communication and trust in the decision)

statistically significant. At 3 months follow-up, intensification of

these differences in effect size and statistical significance and shows

trends in health outcomes. We will present results for 6 and 12

months.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.742

EW625

Four years follow-up in a naturalistic

study of adults with ADHD treated

with atomoxetine

V. Richarte Fernández

1 ,

, M .

Corrales de la Cruz

2 ,

P. Ibá˜nez Jiménez

2 , M.

Corominas Rosso

1 , R. V

idal Estrada

1 ,

C. Fadeuilhe Grau

2 , R.F

. Palma-Álvarez

2 , M.

Casas Brugué

1 ,

J.A. Ramos-Quiroga

1

1

University Hospital Vall d’Hebron, Department of

Psychiatry-CIBERSAM, Barcelona, Spain

2

University Hospital Vall d’Hebron, Department of Psychiatry,

Barcelona, Spain

Corresponding author.

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is

a psychiatric chronic disorder of childhood that persists into ado-

lescence and adulthood in the most part of cases. There are various

ways of treating ADHD.

Objectives

Assess the effectiveness and tolerability of atom-

oxetine long-term and routine clinical practice in adult ADHD

treatment. Study the clinical profile of the patients who take ato-

moxetine.

Aims

The aim of this is to study the treatment of ADHD in adults

with a non-stimulant drug atomoxetine.

Methods

We obtain results from 126 patients recruited from July

2009 to May 2013 who have been prescribed Atomoxetine as a

treatment for ADHD from the hospital pharmacy.

Results

Comorbid disorders were presented in 57.1% of the

patients included at the study (25.3% of which belong to the

group of anxiety disorders). The use of other psychotropic drugs

associated with atomoxetine was observed in 54.8% of patients.

The 62.7% of the patients concerned continued treatment beyond

225 weeks (4 years 3 months) of observation. The Clinical Global

Impression Improvement scale (CGI-I) and side effects determine

monitoring treatment. A total of 61.9% of patients responded sat-

isfactory to treatment with atomoxetine getting the CGI-I scale

a score of 1-2. The duration of therapy and patient age are fac-

tors that influence the response. Furthermore, the clinical profile